Gammacan Engages Global Markets Capital Group to Actively Pursue Strategic Alliances in the Blood, Plasma And IVIg Markets

      Specialists in Life Sciences Industry with Track Record of
   Consummating Successful M&A and Corporate Transactions to Assist
               Company in Achieving Strategic Objectives

   Gammacan International (OTCBB:GCAN), a developer of
immunotherapies for cancer and other diseases, today announced that it
has engaged Global Markets Capital Corporation ("GMCG"), an
independent investment bank focused in the life sciences industry and
specializing in structuring and executing corporate transactions, to
assist the Company in achieving its strategic objective of partnering
with leaders in the blood, plasma and IVIg markets.
   "We believe that the development of IVIg based products for the
treatment of metastatic cancer have advanced to a stage that Gammacan
is ready to explore various options of key synergistic "partnerships"
with IVIg manufacturers, plasma collectors, and other players in the
plasma industry," stated Vered Caplan, CEO.
   Mark R. Saunders, President of Global Markets Capital Group, LLC,
stated, "Global Markets Capital Group is extremely pleased to work
with Gammacan, an emerging leader in the IVIg field. We look forward
to support Gammacan through strategic transactions that will further
the Company's efforts to develop and commercialize its products and
that will provide them with greater exposure in the capital markets."

   About Global Markets Capital Group

   Global Markets Capital Group, LLC (GMCG, LLC) is a New York based
independent investment banking firm with offices in Sydney, Australia
that provides innovative strategic advisory services and mergers and
acquisitions expertise globally to public and private life science
companies. Global Markets Capital Group currently represents a number
of the leading life science companies in the US and Europe, as well as
a large number of the leading publicly traded life science companies
in Australia.
   For further information on Global Markets Capital Group visit
www.globalmarketscapital.com.

   About Gammacan:

   Gammacan is focusing on the commercialization of a revolutionary
anti-cancer immunotherapy that the Company believes will be proven to
be effective in reducing the metastatic spread of a wide range of
cancers. Gammacan's proposed treatment is based on IVIg, a safe,
relatively non-toxic human plasma-based product, currently used to
treat a variety of immune deficiencies and autoimmune diseases. It
works by strengthening the patient's immune system. Many experts
currently view immunotherapy as a future alternative to today's
standard chemotherapy. Approximately twenty companies produce IVIg,
and annual worldwide sales are currently in excess of 50 metric tones
with an estimated value in excess of 1.5 billion USD. IVIg is commonly
used to treat certain autoimmune diseases and blood disorders and to
replace the antibodies in people who are unable to produce them. For
more information about Gammacan visit www.gammacan.com or call the
company's headquarters in Givat Shmuel, Israel at 972 3 5774475.

   Safe Harbor Statement:

   Statements in this document that are not purely historical are
forward-looking statements. Forward-looking statements in this release
include statements regarding: the commercialization of an anti-cancer
immunotherapy and the Company developing the boosting of cancer
patients' immune systems with IVIg into an effective treatment. Actual
outcomes and the Company's actual results could differ materially from
those in such forward-looking statements. Factors that could cause
actual results to differ materially include risks and uncertainties
such as the inability to finance the planned development of the
technology, inability to hire appropriate staff to develop the
technology, unforeseen technical difficulties in developing the
technology, inability to obtain regulatory approval for human use,
competitors' therapies proving more effective, cheaper or otherwise
preferable for consumers, inability to market the product we produce,
among other factors, all of which could among other things, delay or
prevent product release or cause our company to fail. For further risk
factors see the risk factors associated with other early stage medical
research and development companies filed with the SEC on Edgar.